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Três complexos de PdII com tiossemicarbazonas N(4)-substituídas foram preparados: [Pd(aptsc)
(PPh3)](NO3)•H2O, 1, [Pd(apmtsc)(PPh3)](NO3), 2, e [Pd(apptsc)(PPh3)](NO3)•H2O, 3, sendo 
PPh3 = trifenilfosfina; Haptsc = 2-acetilpyridina-tiossemicarbazona; Hapmtsc = 2-acetilpiridina-
N(4)-metil-tiossemicarbazona e Happtsc = 2-acetilpiridina-N(4)-fenil-tiossemicarbazona. Os 
complexos foram caracterizados por análise elementar, IR, UV-Vis, 1H e 31P{1H} NMR e tiveram 
suas estruturas cristalinas determinadas por difratometria de raios X em monocristal. Os ligantes 
tiossemicarbazonatos monoaniônicos atuam de modo tridentado, ligando-se ao metal pelos átomos 
de nitrogênio piridínico, nitrogênio azometínico e enxofre. A atividade citotóxica frente à linhagem 
de células tumorais MDA-MB231 (tumor de mama) e a atividade anti-Mycobacterium tuberculosis 
H37Rv ATCC 27294 dos compostos foram investigadas. Os complexos de PdII mostraram-se 
altamente ativos contra as células tumorais, com valores de IC50 em torno de 5 μmol L-1, enquanto 
o agente antitumoral em uso clínico cisplatina mostrou-se inativo. Os compostos apresentaram 
atividade anti-M. tuberculosis significante, com valores de CIM comparáveis ou melhores que 
aqueles referentes a alguns fármacos usados clinicamente contra tuberculose.
Three PdII complexes were prepared from N(4)-substituted thiosemicarbazones: [Pd(aptsc)
(PPh3)](NO3)•H2O, 1, [Pd(apmtsc)(PPh3)](NO3), 2, and [Pd(apptsc)(PPh3)](NO3)•H2O, 3, where 
PPh3 = triphenylphosphine; Haptsc = 2-acetylpyridine-thiosemicarbazone; Hapmtsc = 
2-acetylpyridine-N(4)-methyl-thiosemicarbazone and Happtsc = 2-acetylpyridine-N(4)-phenyl-
thiosemicarbazone. All complexes were characterized by elemental analysis, IR, UV-Vis, 1H 
and 31P{1H} NMR spectroscopies, and had their crystalline structures determined by X-ray 
diffractometry from single crystals. The monoanionic thiosemicarbazonate ligands act in a 
tridentate mode, binding to the metal through the pyridine nitrogen, the azomethine nitrogen and 
the sulfur atoms. The cytotoxic activity against the breast cancer cell line MDA-MB231 and the 
anti-Mycobacterium tuberculosis H37Rv ATCC 27294 activity were evaluated for the compounds. 
All PdII complexes were highly active against the studied cell line, presenting similar values of 
IC50, around 5 μmol L-1, while the clinically applied antitumor agent cisplatin was inactive. The 
compounds show remarkable anti-M. tuberculosis activities, presenting MIC values comparable 
or better than some commercial anti-M tuberculosis drugs.
Keywords: palladium(II) complexes, thiosemicarbazones, cytotoxicity, breast tumor cells, 
Mycobacterium tuberculosis 
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Introduction
There has been much interest in the development 
of effective agents against tumor cell lines resistant to 
cisplatin, as well as of more efficient anti-tuberculosis drugs. 
Cisplatin has received much attention recently with regard 
to metal-based chemotherapy due to its disadvantages, 
such as the occurrence of primary or acquired resistance.1-3 
On the other hand, the rising incidence of tuberculosis, 
especially when associated with AIDS cases, and the 
occurrence of multidrug-resistant tuberculosis demand the 
development of new anti-tubercular drugs.4,5 To attenuate 
these disadvantages, much effort has been directed toward 
the development of new antitumor metal coordination 
compounds with the ability to overcome cisplatin6 
resistance, as well as of new drugs addressing the current 
problems with tuberculosis therapy. 
Until some time ago, the great majority of antitumor 
metal complexes synthesized and characterized were 
structural analogs of cisplatin.7 However, there has been 
a decrease in the number of new compounds of this type 
because they have not shown improved clinical efficacy, 
most likely because all cis-[PtX2(amine)2] compounds 
show similar DNA-binding modes, and therefore similar 
biological effects.2,8 
Thiosemicarbazone derivatives have received 
considerable attention due to their pharmacological 
properties, such as antiviral, antibacterial and antitumor 
activities.9-13 The compound triapine, which is currently 
being tested in a Phase I clinical trial against a variety 
of tumor cell models,1 and thiacetazone, which has been 
widely used in the treatment of tuberculosis,4 are good 
examples of the biologic activity of this class of compounds.
Structure-activity relationships not only evidence 
that the complexation with a metal enhances the 
antimicrobial activity of the ligands against some tested 
microorganisms, but also indicate that the metal plays a 
relevant role.14-16 It has already been shown, for example, 
that Pd-thiosemicarbazone complexes possess interesting 
antiproliferative effects on human breast cancer, including 
tumor cell lines resistant to cisplatin17-20 and have also 
presented good antimycobacterial effects.21 The presence 
of phosphine ligands in potential anti-cancer complexes 
is supposed to provide better cytotoxicity by enhancing 
lipophilicity – and consequently permeability through the 
cell membrane.22 Thus, our group focused on investigating 
both antitumor and antimycobacterial activities of some 
PdII complexes containing both thiosemicarbazone and 
phosphine ligands. 
This work reports the preparation, structural 
characterization, cytotoxicity against breast cancer cells 
and anti-M. tuberculosis activity of three thiosemicarbazone 
derivatives and their PdII complexes containing 
different N(4)-substituted groups: 2-acetylpyridine-
thiosemicarbazone (Haptsc), 2-acetylpyridine-N(4)-methyl-
thiosemicarbazone (Hapmtsc) and 2-acetylpyridine-N(4)-
phenyl-thiosemicarbazone (Happtsc).
Experimental
Materials and measurements
[PdCl2(PPh3)2], AgNO3 and other analytical grade 
reagents and solvents were obtained commercially (Aldrich 
or Strem Chemicals) and used without further purification. 
The complexing agents Haptsc, Hapmtsc and Happtsc 
were prepared by standard methods described in the 
literature.23 FTIR spectra were recorded using KBr pellets 
on a BOMEM FTIR model BM 100 spectrophotometer 
in the 4000-400 cm–1 region. The electronic spectra were 
recorded with a JASCO V-630 spectrophotometer. NMR 
spectra were acquired using a Varian MERCURY Plus 
spectrometer operating at 300.07 and 121.47 MHz for 
1H and 31P, respectively. The 1H spectra were internally 
referenced to tms (tetramethylsilane). The 31P{1H} spectra 
were externally referenced to H3PO4 (85%, d = 0) with 
positive chemical shifts downfield the standard. Elemental 
analyses (CHNS) were carried out using a FISONS EA-
1108 analyzer. A Bruker CCD X8 APEX II diffractometer 
was used for the X-ray structure analyses of 1 and 2, while 
the data collection for 3 was performed on a NONIUS 
KAPPA CCD diffractometer. Both equipments were 
operated using graphite monochromator and Mo-Kα
 
radiation (λ = 71.073 pm). 
Crystal structure determinations 
Orange crystals of the complexes 1, 2 and 3 were 
obtained by slow evaporation of their methanolic solutions 
at room temperature. The structures were solved using 
SHELXS9724 by direct methods. All non-hydrogen atoms 
were refined with anisotropic displacement parameters 
using SHELXL97.25 The hydrogen atom positions were 
found in the Fourier map or calculated at idealized 
positions. More detailed information on the structure 
determinations is given in Table 1.
Cell culture and cytotoxicity determination 
In vitro cytotoxicity assays on cultured human tumor 
cell line still represent the standard method for the initial 
screening of antitumor agents. Thus, as a first step to assess 
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their pharmacological properties, the new palladium(II) 
complexes were assayed against the human breast tumor 
MDA-MB-231 cell line (ATCC No. HTB-26). The cells 
were routinely maintained at 37 ºC in a humidified 5% 
CO2 atmosphere with Dulbecco’s Modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS). After reaching confluence, the cells were 
detached by tripsinization and counted. For the cytotoxicity 
assay, 4 × 104 cells well–1 were seeded in 200 μL of 
complete medium in 96-well plates (Corning Costar). 
The plates were incubated at 37 ºC in 5% CO2 for 24 h 
to allow cell adhesion prior to drug testing. The complex 
was dissolved in sterile dimethylsulfoxide (dmso, stock 
solution with maximum concentration of 20 mmol L-1) and 
diluted to 10, 2, 0.2 and 0.02 mmol L-1. Two microliters 
of each complex sample were added to 200 μL medium 
(without FBS), so that the final concentration of dmso in 
each well was approximately 1% and the complex was 
diluted approximately 100 times. The other compounds 
evaluated (free thiosemicarbazones and cisplatin) were 
Table 1. X-ray structure data collection and refinement parameters for complexes 1-3
1 2 3
Empirical formula C26H26N5O4PPdS C27H26N5O3PPdS C32H30N5O4PPdS
Formula weight, M 641.95 637.96 718.04
Temperature, T (K) 293(2) 293(2) 293(2)
Crystal system Triclinic Triclinic Orthorhombic
Space group P –1 P –1 Pbca
Unit cell dimensions
a (pm) 947.95(11) 951.81(3) 1027.160(10)
b (pm) 950.32(10) 968.73(3) 1970.01(3)
c (pm) 1602.98(18) 1584.61(5) 3095.18(5)
α (°) 75.891(6) 74.049(2) 90
β (°) 74.750(6) 77.072(2) 90
γ (°) 84.187(7) 84.664(2) 90
Volume, V (nm3) 1.3501(3) 1.36845(7) 6.26314(15)
Z 2 2 8
Density calculated (Mg/m3) 1.582 1.548 1.523
Absorption coefficient (mm-1) 0.866 0.851 0.756
F(000) 652 648 2928
Crystal size (mm3) 0.410 × 0.170 × 0.130 0.790 × 0.550 × 0.260 0.840 × 0.400 × 0.360
Method / q Range for data collection (o) j and ω scans / 2.21 to 28.15 j and ω scans / 2.19 to 30.63 j and ω scans with k offsets / 
2.94 to 27.49
Limiting indices (h, k, l) −12←h←12, 
−12←k←12, 
−21←l←21
−13←h←13, 
−13←k←13, 
−22←l←22
−13←h←12, 
−25←k←25, 
−39←l←39
Reflections collected 26183 34380 56101
Reflections unique/ Rint 6589 [R(int) = 0.0306] 8357 [R(int) = 0.0682] 7165 [R(int) = 0.0713]
Completeness to theta 28.15 (99.6 %) 30.63 (98.9 %) 27.49 (99.7 %)
Data/restraints/parameters 6589 / 0 / 349 8357 / 0 / 343 7165 / 0 / 403
Absorption correction Gaussian Gaussian Multi-scan
Min. and max. transmission 1.000000 and 0.835097 0.976719 and 0.667818 0.889 and 0.946
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2 Full-matrix least-squares on F2
Hydrogen treatment mixed mixed riding model
Final R indices [I > 2s(I)] R1 = 0.0354, 
wR2 = 0.1010
R1 = 0.0497, 
wR2 = 0.1345
R1 = 0.0355, 
wR2 = 0.085
R indices (all data) R1 = 0.0471, 
wR2 = 0.1196
R1 = 0.0787, 
wR2 = 0.1590
R1 = 0.0599, 
wR2 = 0.0964
Goodness-of-fit, S 1.123 1.049 1.045
Largest diff. peak and hole (e Å-3) 1.114 and -0.763 1.671 and -1.537 0.424 and -0.636
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also dissolved in sterile dmso. The cells were exposed 
to the complex for 48 h. Cell respiration, as an indicator 
of cell viability, was determined by the mitochondrial-
dependent reduction of MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) to formazan.26 MTT 
solution (0.5 mg mL-1) was added to the cell cultures and 
incubated for 3 h. Thereafter, 100 μL of isopropanol were 
added in order to dissolve the formazan crystals. The 
conversion of MTT to formazan by metabolically viable 
cells was monitored by an automated microplate reader at 
570 nm. The percentage of cell viability was calculated by 
dividing the average absorbance of the cells treated with the 
compounds by that of the control; % of the cell viability 
versus drug concentration (logarithmic scale) was plotted 
to determine the IC50 (drug concentration at which 50% of 
the cells are viable relative to the control), with its estimated 
error derived from the average of 3 trials.
Anti-Mycobacterium tuberculosis activity assay
The anti-M. tuberculosis activity was determined 
applying the Microplate Alamar Blue Assay (MABA) 
as the analytical method.27 Stock solutions of the tested 
compounds were prepared in dmso27 and were diluted in 
Middlebrook 7H9 (Difco) broth supplemented with oleic 
acid, albumin, dextrose and catalase (OADC enrichment - 
BBL/Becton-Dikinson, Sparks, MD, USA) to obtain final 
sample concentration ranges from 1.00 to 100 μg mL-1. 
Isoniazid was dissolved in distilled water according to 
the manufacturers’ recommendations (Difco laboratories, 
Detroit, MI, USA) and used as a positive control drug. M. 
tuberculosis H37Rv ATCC 27294 was grown for 7 to 10 
days in Middlebrook 7H9 supplemented with OADC and 
added of 0.05% Tween 80 to avoid clumps. Suspensions 
were prepared and their turbidities matched to the optical 
density of the McFarland No. 1 standard. After further 
dilution of 1:25 in Middlebrook 7H9 supplemented with 
OADC, the inoculum was added to each well of the 96-well 
microtiter plates (Falcon 3072; Becton Dickinson, Lincoln 
Park, NJ) together with the compounds. Samples were 
set up in triplicate. Cultures were incubated for 7 days at 
37 oC and then Alamar Blue was added for reading. The 
minimum inhibitory concentration (MIC) was defined as 
the lowest concentration of the tested compound necessary 
to inhibit 90% growth of M. tuberculosis. 27 MIC values 
were determined by fluorescence on a SPECTRAfluor 
Plus microfluorimeter (Tecan), with excitation at 530 nm 
and emission at 590 nm.28 As a control, the MIC value 
of isoniazid was determined for each microplate. The 
acceptable MIC of isoniazid ranged from 0.015 to 
0.05 μg mL-1.28
Preparation of [Pd(aptsc)(PPh3)](NO3) •H2O (1), 
[Pd(apmtsc)(PPh3)](NO3) (2) and [Pd(apptsc)(PPh3)]
(NO3)•H2O (3)
Three different solutions of AgNO3 (0.068 g, 0.4 mmol) 
in MeOH (10 mL) were prepared and mixed with 
suspensions of [PdCl2(PPh3)2] (0.128 g, 0.2 mmol) in 
MeOH (20 mL). The resulting mixtures were kept under 
reflux until the formation of red solutions (approximately 
30 min). The precipitates formed (AgCl) were filtered off 
and each filtrate received the addition of 0.2 mmol of one of 
the free thiosemicarbazones (0.039 g, 0.042 g and 0.054 g 
for Haptsc, Hapmtsc and Happtsc, respectively) dissolved 
in MeOH (15 mL). The resulting mixtures were kept under 
reflux for 2 h, forming yellow solutions, which gave orange 
crystals of complexes 1, 2 and 3 after slow evaporation at 
room temperature. The crystals were washed with small 
portions of cold CH2Cl2 and n-hexane, yielding 0.039 
(31.0%), 0.039 (30.3%) and 0.050 g (34.8%) of 1, 2 and 
3, respectively. Elemental analysis: Complex 1 (641.98 g 
mol-1): Found: C, 48.82; H, 4.27; N, 10.93; S, 5.35. Calc. 
for C26H26N5O4PPdS: C, 48.64; H, 4.08; N, 10.91; S, 
4.99%. Complex 2 (637.99 g mol-1): Found: C, 50.21; 
H, 4.25; N, 10.85; S, 4.80. Calc. for C27H26N5O3PPdS: C, 
50.83; H, 4.11; N, 10.98; S, 5.03%. Complex 3 (718.08 g 
mol-1): Found: C, 53.44; H, 4.34; N, 10.12; S 4.30. Calc. 
for C32H30N5O4PPdS: C, 53.53; H, 4.21; N, 9.75; S, 4.46%. 
UV-Vis data, CH2Cl2 solution [λmax/nm (log ε)] for 1: 308 
(4.47), 369 (4.16), 447 (3.72). Complex 2: 309 (4.41), 380 
(4.23), 466 (3.70). Complex 3: 316 (4.29), 420 (4.47).
Results and Discussion
Spectroscopic characterization
The main IR vibrational  bands of the free 
thiosemicarbazones and their complexes are listed in 
Table 2. Upon coordination, changes in the ν(C=S), 
ν(C=C + C=N) and ν(N–H) wavenumbers, in comparison 
to the values found for the thiosemicarbazones, were 
observed for complexes 1-3. They are consistent with the 
tridentate coordination of the thiosemicarbazone derivatives 
through the thiolate sulfur, the azomethine nitrogen and the 
pyridine nitrogen atoms, respectively.29 The occurrence of 
the ν(N−N) band at higher frequencies in the IR spectra of 
the complexes, compared to those observed for the ligands, 
confirms coordination through the azomethine nitrogen 
atom.11 The ν(C=S) bands at 801-850 cm−1 in the spectra 
of free thiosemicarbazones shift to the 780-784 cm−1 range 
in the complexes, indicating coordination through the sulfur 
atom. These shifts to lower frequencies are compatible 
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with deprotonation and formation of a C–S single bond.23 
A very strong band found at 1384 cm−1 in the spectra of 
the complexes is attributed to ν(NO3−). 
The presence of the triphenylphosphine ligand is 
confirmed in the spectra of the complexes by the existence 
of the characteristic bands around 1097 cm−1 for ν(P–C), 
with no significant change when compared to the precursor 
[PdCl2(PPh3)2].
The data obtained from the electronic spectra of the 
complexes in CH2Cl2 solutions are given in the experimental 
section. Three d–d spin allowed singlet-singlet and three 
spin forbidden singlet-triplet transitions are predicted for 
square-planar complexes of palladium(II). However, strong 
charge-transfer transitions may interfere and prevent the 
observation of some of the expected bands, especially 
for complexes containing sulfur donor atoms.11,17 The 
prominent strong bands in the 308-466 nm range are 
assigned to a combination of intraligand and ligand to 
metal charge transfer (LMCT) absorptions and d–d bands, 
which support the idea of a square-planar environment for 
the metal ions. 
The 1H NMR data for the free thiosemicarbazones and 
complexes 1, 2 and 3 are given in Table 3. Figure 1 shows 
the numbered structures of the free thiosemicarbazones. 
The three new PdII complexes show similar 1H-chemical 
shift behavior. Some hydrogen atom values of d were not 
observed precisely due to overlapping with the signals 
of the aromatic hydrogen atoms of triphenylphosphine. 
1H NMR integrations and signal multiplicities are in 
agreement with the proposed structures.
In the 1H NMR spectra of the complexes 1, 2 and 3, 
a high frequency shift of ca. 0.15 ppm for the methyl 
hydrogen atoms (C–CH3), compared to the spectra of the 
thiosemicarbazones, evidences the coordination through the 
azomethine nitrogen. On the other hand, the signals referred 
to the hydrogen atoms of the methyl group (N–CH3), 
observed in the spectrum of 2, remain almost non shifted 
in relation to free Hapmtsc. The methyl group bonded to 
the N4 atom (6 in the numbering scheme) is observed in 
the spectrum of Hapmtsc as a doublet, which is consistent 
with a coupling to the hydrogen atom bonded directly to 
the N4 atom. In complex 2, however, this signal is observed 
as a sharp singlet, similarly to what is reported for a PdII 
complex containing the ligands apmtsc− and Cl−.12 The 
spectrum of free Haptsc displayed three signals related 
to N-bonded H atoms, showing non-equivalence for the 
hydrogens bonded to N4. In complex 1 only one NH signal 
is observed, which is consistent with the deprotonation of 
N3 and with the chemical equivalence of the NH2 protons.
The 31P{1H} NMR spectrum of the precursor 
[PdCl2(PPh3)2] in CD2Cl2 solution shows a singlet peak 
for the phosphorous donor atoms at d 23.83 ppm. In the 
spectra of complexes 1, 2 and 3, this singlet peak is shifted 
to 28.10, 28.22 and 28.25 ppm, respectively, in conformity 
with the presence of only one species for each complex in 
the CD2Cl2 solution. 
Table 2. Relevant IR spectral assignments (cm–1) for the free thiosemicarbazones and complexes 1-3
Compounds ν(N–H) ν(C=C, C=N) ν(NO) ν(P–C) ν(N–N) ν(CS)
Haptsc 3374, 3261, 3184 1609, 1583, 1563, 
1502, 1467, 1430 
- - 994 850
Hapmtsc 3289, 3240 1578, 1539, 1497, 
1461, 1433
- - 989 834
Happtsc 3301, 3242 1598, 1587, 1527, 
1468, 1444
- - 978 801
1 3284, 3129 1598, 1584, 1563, 
1505, 1456, 1434
1384 1098 997 784
2 3200 1589, 1567, 1541, 
1510, 1461, 1435
1384 1097 996 783
3 3262 1601, 1560, 1509, 
1459, 1437
1384 1097 996 780
Figure 1. Structural representation of the thiosemicarbazones with the numbering scheme employed in the NMR spectroscopy section.
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Crystal structure of the complexes
Table 4 contains selected interatomic distances and 
angles for the complexes [Pd(aptsc)(PPh3)](NO3)•H2O 
(1), [Pd(apmtsc)(PPh3)](NO3) (2) and [Pd(apptsc)(PPh3)]
(NO3)•H2O (3). ORTEP drawings of the products, with an 
atomic numbering scheme, are shown in Figures 2, 3 and 
4, respectively. 
All complexes are cationic, with a nitrate anion as 
counter ion. Products 1 and 3 also have a water molecule as 
solvate. In all complexes, the palladium(II) ion is in a quite 
similar, nearly planar, fourfold environment. The metal is 
coordinated to the negatively charged organic molecule 
through the pyridine nitrogen atom [Pd–N bond distances 
of 210.2(3) pm for 1, 210.1(3) pm for 2 and 208.8(2) pm 
for 3], the azomethine N-atom [at slightly shorter Pd–N 
distances of 202.4(3), 203.2(3) and 200.6(2) pm for 1, 2 
and 3, respectively] and the sulfur atom [Pd–S distances 
of 225.36(9), 225.15(11) and 224.07(7) pm for 1, 2 and 
3, respectively]. This forms two five-membered chelate 
rings including the PdII atom and with bond dimensions 
comparable to those observed for similar square-planar PdII 
complexes.11,29 The remaining binding site is occupied by a 
phosphorous atom [Pd–P distances of 229.39(8), 229.23(9) 
and 227.57(7) pm for 1, 2 and 3, respectively]. 
The stronger coordination of the metal to the azomethine 
nitrogen compared to the pyridyl nitrogen is attributed to the 
higher basicity of N(2).18 The largest deviation in the bond 
angles from those expected for square planarity is found 
for the angle N(1)–Pd–S, in which an average deviation, 
considering the three complexes, is of 16.7º below the 
expected value of 180º. 
In complex 1, the crystal structure is stabilized by a 
net of intermolecular hydrogen bonds toward the direction 
[001], parallel to the c axis, which is shown in Figure S1 
(Supplementary Information, SI). The nitrogen atom N(4), 
of the NH2 group, is H-bonded through H(41) to the O(2) 
atom from a nitrate ion, while H(42) interacts with a hydrate 
water oxygen atom, O(4). Furthermore, the oxygen atom 
O(4) is H-bonded through H(4a) to the O(1b) and O(3b) from 
a symmetry-generated nitrate ion and through H(4b) to the 
Table 3. 1H NMR data (ppm) for the thiosemicarbazones and complexes 1-3 at room temperature
Compound Assignments
Haptsc 1H NMR (dmso-d6) d 2.39 (s, 3 H, CH3), 7.38 (ddd, J2,3 8 Hz, J2,1 5 Hz, J2,4 1 Hz, 1 H, CH), 7.79 (ddd, J3,4 J3,2 8 Hz, J3,1 2 Hz, 1 H, CH), 
8.15 (s, 1 H, NH), 8.42 (s, 1 H, NH), 8.44 (ddd, J4,3 8 Hz, J4,2 1 Hz, 1 H, CH), 8.58 (ddd, J1,2 5 Hz, J1,3 2 Hz, 1 H, CH), 10.33 (s, 1 H, NH).
Hapmtsc 1H NMR (dmso-d6) d 2.38 (s, 3 H, CH3), 3.06 (d, J6,5 5 Hz, 3 H, N–CH3), 7.39 (ddd, J2,3 7 Hz, J2,1 5 Hz, J2,4 1 Hz, 1 H, CH), 7.82 (ddd, J3,4 
8 Hz, J3,2 7 Hz, J3,1 1 Hz, 1 H, CH), 8.42 (dq, J4,3 8 Hz, J4,2 1 Hz, 1 H, CH), 8.58 (dq, J1,2 5 Hz, J1,3 1 Hz, 1 H, CH), 8.64 (d, J5,6 5 Hz, 1 H, 
CH), 10.35 (s, 1 H, NH).
Happtsc 1H NMR (dmso-d6) d 2.47 (s, 3 H, CH3), 7.24 (ddd, J7,6 7 Hz, J7,5 1 Hz, 1 H, CH), 7.34-7.44 (m, 3 H, CH), 7.55 (dd, J5,6 9 Hz, J5,7 1 Hz, 2 
H, CH), 7.82 (ddd, J3,4 J3,2 8 Hz, J3,1 2 Hz, 1 H, CH), 8.54 (ddd, J4,3 8 Hz, J4,2 J4,1 1 Hz, 1 H, CH), 8.61 (ddd, J1,2 5 Hz, J1,3 2 Hz, J1,4 1 Hz, 1 
H, CH), 10.21 (s, 1 H, NH), 10.67 (s, 1 H, NH).
1 1H NMR (CD2Cl2) d 2.50 (s, 3 H, CH3), 5.97 (s, 2 H, NH2), 7.02 (ddd, J2,3 8 Hz, J2,1 5 Hz, J2,4 2 Hz, 1 H, CH), 7.19 (d, J1,2 5 Hz, 1 H, CH), 
7.49-7.74 (m, 16 H, PPh3 + CH), 8.01 (ddd, J3,2 8 Hz, 1H). 
2 1H NMR (CD2Cl2) d 2.52 (s, 3 H, CH3), 3.02 (s, 3 H, CH3), 6.95-8.05 (m, 21 H, PPh3 + CH).
3 1H NMR (CD2Cl2) d 2.64 (s, 3 H, CH3), 7.04-7.14 (m, 2 H, CH), 7.23 (d, J7,6 8 Hz, 1 H, CH), 7.34 (t, J5,6 8 Hz, 2 H, CH), 7.49-7.73 (m, 18 
H, PPh3 + CH), 7.85 (d, J1,2 8 Hz, 1 H, CH), 8.08 (ddd, J3,4 J3,2 8 Hz, 1 H, CH).
Table 4. Selected bond lengths (pm) and angles (°) refined from X-ray 
data for 1-3
1 2 3
Bond Lengths
Pd–N(1) 210.2(3) 210.1(3) 208.8(2)
Pd–N(2) 202.4(3) 203.2(3) 200.6(2)
Pd–S 225.36(9) 225.15(11) 224.07(7)
Pd–P 229.39(8) 229.23(9) 227.57(7)
S–C(8) 177.6(4) 176.8(4) 176.7(3)
N(3)–N(2) 136.7(4) 136.3(4) 137.0(3)
P–C(11) 181.8(3) 182.4(4) 182.3(3)
P–C(21) 182.9(3) 181.0(3) 180.9(3)
P–C(31) 182.6(3) 182.7(4) 181.5(3)
N(5)–O(1) 115.5(6) 114.0(7) 121.6(4)
N(5)–O(2) 118.4(6) 121.8(8) 123.9(4)
N(5)–O(3) 127.6(7) 119.9(9) 120.2(4)
Bond Angles
N(2)–Pd–N(1) 79.54(11) 79.43(12) 79.62(8)
N(2)–Pd–S 83.55(9) 83.87(9) 84.22(6)
N(1)–Pd–S 162.88(8) 163.29(9) 163.67(6)
N(2)–Pd–P 174.95(8) 177.64(9) 175.82(6)
N(1)–Pd–P 102.86(7) 102.80(9) 102.13(6)
S–Pd–P 94.20(3) 93.90(4) 93.84(3)
C(8)–S–Pd 95.89(13) 95.81(14) 95.48(9)
C(1)–N(1)–Pd 130.9(2) 130.7(3) 130.1(2)
C(5)–N(1)–Pd 110.8(2) 111.2(2) 111.2(2)
C(8)–N(3)–N(2) 112.2(3) 112.5(3) 111.4(2)
C(6)–N(2)–Pd 117.1(2) 116.8(3) 117.8(2)
N(3)–N(2)–Pd 123.2(2) 122.5(2) 123.1(2)
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N(3a) atom from a symmetry-related complex molecule. The 
crystalline structure of complex 2 is stabilized by hydrogen 
interactions involving the nitrogen atom N(4) and the oxygen 
atoms O(2) and O(1), as shown in Figure S2. As observed 
in 2, the crystal structure of complex 3 is also stabilized by 
hydrogen bonds, but in a different mode. The nitrogen atom 
N(4) is H-bonded through H(41) to a symmetry generated 
oxygen atom O(4b) from a hydrate water molecule, while the 
same oxygen O(4) atom is H-bonded through H(411b) to the 
oxygen atom O(1b) of a nitrate ion, as shown in Figure S3. 
The distances, angles and symmetry operations related to 
the hydrogen bonds are given in Table S1.
Cytotoxic activity
The palladium(II) complexes and the respective free 
thiosemicarbazones were evaluated for their effectiveness 
against the breast tumor cell line MDA-MB231. For 
comparison purposes, the cytotoxicity of cisplatin was 
evaluated under the same experimental conditions. The 
values of cell viability were calculated after the tested 
compounds were incubated for 48 h (Figure 5). The IC50 
values, calculated from the dose-survival curves from MTT 
assay, are shown in Table 5. 
Comparing only the values of IC50 of the free 
thiosemicarbazones, the order of cytotoxic activity was 
Happtsc > Hapmtsc > Haptsc, suggesting that the activity 
is increased by the presence of bulky groups bonded to 
Figure 2. An ORTEP view of [Pd(aptsc)(PPh3)](NO3)•H2O (1) with the 
thermal ellipsoids at the 50% probability level. The labeling scheme used 
for the phenyl rings is omitted for clarity.
Figure 3. An ORTEP view of [Pd(apmtsc)(PPh3)](NO3) (2) with the 
thermal ellipsoids at the 50% probability level. The labeling scheme used 
for the phenyl rings is omitted for clarity.
Figure 4. An ORTEP view of [Pd(apptsc)(PPh3)](NO3)•H2O (3) with the 
thermal ellipsoids at the 50% probability level. The labeling scheme used 
for the phenyl rings is omitted for clarity.
Figure 5. The effect of the thiosemicarbazones and their PdII complexes 
on the viability of MDA-MB-231 cells. Cell proliferation was determined 
after 2 days of culturing in the presence of different concentrations of 
tested compounds and estimated by colorimetric assay (MTT) as described 
in Experimental section. The data represent a mean of three independent 
experiments ± SD. [ ]/(μmol L-1) = 200/20/2/0.2.
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N(4) of the thiosemicarbazone. On the other hand, all 
palladium complexes presented values of IC50 around 
5 μmol L-1, showing no significant variation on the activity 
due to the changes in the groups bonded to the N(4) of the 
thiosemicarbazone ligands. The palladium complexes were 
more active than the free thiosemicarbazones, except for 
complex 3, whose thiosemicarbazone precursor Happtsc 
had an IC50 value around 3 μmol L-1. The palladium 
complex 2 presented an activity five times higher than 
that from Hapmtsc. In addition, the Haptsc and cisplatin 
were ineffective against the tested cell line, with the IC50 
value over 200 μmol L-1. A comparison with the precursor 
compound [PdCl2(PPh3)2] was not possible due to the 
lack of solubility in dmso, even at the concentration of 
2 μmol L-1. Alternatively, [PdCl2(MeCN)2] and PPh3 
were tested, showing no activity at the concentration of 
200 μmol L-1. The good values of activity found for these 
complexes, around 5.0 μmol L-1, show that the complexation 
of thiosemicarbazone to PdII may be a good strategy to 
obtain antitumor agents, although in this case the free 
Happtsc presented the best result. 
The similarity of the values of IC50 found for the 
PdII complexes is an evidence in favor of the same 
biochemical action mechanism, but different from those 
of the cisplatin, inactive in this case, and of the free 
thiosemicarbazones, which varied from inactive (Haptsc) 
to a significant activity (Happtsc). In fact, the literature 
reports that palladium(II) and platinum(II) complexes of 
thiosemicarbazone derivatives are able to bind to DNA in 
vitro, and present enhanced capacity to form interstrand 
crosslinks when compared to cisplatin.30,31 Additionally, 
the presence of a phosphine ligand may also contribute 
to higher activity.32
On the other hand, the free thiosemicarbazones could 
present antitumor effect by inhibiting DNA syntheses 
through the blockage of the enzyme ribonucleoside 
diphosphate reductase (RDR), which catalyses the 
conversion of ribonucleotides into desoxyribonucleotides, as 
proposed for other α(N)-heterocyclic thiosemicarbazones.33 
Anti-Mycobacterium tuberculosis activity
The in vitro antimycobacterial activities of the three 
thiosemicarbazones and their PdII complexes were assessed 
against the strains of the Mycobacterium tuberculosis H37Rv 
ATCC 27294. The results are exposed in Table 5. 
Comparing the MIC values of the free thiosemicarbazones 
with the values obtained for the complexes, it can be seen 
that, except for 2, the activity of the complexes is much 
higher than those of the uncoordinated thiosemicarbazones. 
Complexes 1 and 3 present approximately 8-fold and 6-fold 
higher activities, respectively, than the respective free 
thiosemicarbazones. 
The activity found for complex 3 is comparable 
to those of some commonly used anti-M. tuberculosis 
agents, like cycloserine (MIC = 122.4-489.7 μmol L-1), 
gentamicin (MIC = 4.19-8.38 μmol L-1), tobramycin 
(MIC = 8.56-17.11 μmol L-1) and clarithromycin 
(MIC = 10.70-21.40 μmol L-1).27 The precursor complex, 
[PdCl2(PPh3)2], as well as the complex [PdCl2(MeCN)2], 
did not show any inhibition at the concentration of 
50 μg mL-1, corresponding to 71.2 and 192.8 μmol L-1, 
respectively, suggesting that the thiosemicarbazonate 
Figure 6. Comparison of the magnitude of the IC50 values of cisplatin, 
free thiosemicarbazones and the respective PdII complexes against breast 
tumor MDA-MB-231 cell line.
Table 5. IC50 values of the thiosemicarbazones, PdII complexes and 
cisplatin against breast tumor MDA-MB-231 cell line and the MIC values 
against the strains of the Mycobacterium tuberculosis H37Rv ATCC 27294
IC50 (μmol L-1) MIC (μg mL-1) MIC (μmol L-1)
Haptsc* > 200 31.3 160.9
1 4.9 ± 0.9 12.5 19.5
Hapmtsc 24.6 ± 11.3 7.8 37.4
2 5.2 ± 1.5 25 39.2
Happtsc 2.8 ± 0.5 15.6 57.7
3 5.5 ± 2.8 6.25 8.7
Cisplatin* > 200 Not measured Not measured
[PdCl2(MeCN)2] > 200 > 50 -
[PdCl2(PPh3)2] Not soluble > 50 -
Isoniazid Not measured 0.015 0.1
*The maximum concentration employed in cytotoxicity tests was 
200 μmol L-1.
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ligands are the active species and that their activity may 
be improved upon complexation to palladium. Previous 
studies explain this fact as a result of the polarity reduction 
of the complex molecule as a whole, when compared with 
the free ions or complexing agents, by partial sharing 
of their charges within the coordination compounds, 
favoring their permeation through the lipid layer of the 
cell membrane, hence resulting in a better cell uptake of 
the active species.34-37
Conclusions
A series of thiosemicarbazones was used to prepare 
novel cationic [PdIIL(PPh3)]+ complexes with nitrate as 
counter ion (1-3). The X-ray studies revealed square-planar 
structures in which the thiosemicarbazonate ligands bind 
in a tridentate monoanionic mode (with loss of the N(3) 
hydrogen atom) by coordination to palladium through the 
pyridine N, azomethine N and thiolate S atoms. The fourth 
coordination site is occupied by neutral PPh3. The crystal 
structure of 1 presents a supramolecular network generated 
by intermolecular hydrogen bonds, while in the structures 
of 2 and 3 only local hydrogen bonds between the cationic 
molecule and a nitrate counter ion are observed. Comparing 
only the values of IC50 of the free thiosemicarbazones, it was 
observed that the activity is increased by the presence of 
bulky groups bonded to N(4). All palladium(II) complexes 
were effective against the studied tumoral cell line, 
presenting high antiproliferative effect, with IC50 values 
around 5 μmol L-1, while the clinically applied antitumor 
agent cisplatin and the precursor compound [PdCl2(PPh3)2] 
were ineffective. The similarity of the IC50 values for the 
PdII complexes indicates that they may have the same 
biochemical action mechanism, other than those of the 
cisplatin and the thiosemicarbazones. The complexes 1 and 
3 show higher anti-M. tuberculosis activities, compared 
to the free thiosemicarbazones, and their actions are 
equivalent or greater than those of some commercial anti-M 
tuberculosis drugs.
Supplementary Information
Crystallographic data have been deposited with the 
Cambridge Crystallographic Data Centre (deposition 
numbers CCDC 743883, CCDC 743884 and CCDC 
743885 for complexes 1, 2 and 3, respectively). Copies of 
available material can be obtained by request to CCDC, 
12 Union Road, Cambridge CB2 1EZ, UK (fax 44-1223-
336033 or e-mail: deposit@ccdc.cam.ac.uk). Table S1 
and Figures S1, S2 and S3 are available free of charge at 
http://jbcs.sbq.org.br. 
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